Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM.

Trial Profile

Phase 2, Double-Blind Randomized, 3-way Cross-Over Liquid Meal Study With Optimal Doses of SC Administered Insulin Lispro With and Without rHuPH20 and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Patients With T2DM.

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2010

At a glance

  • Drugs Hyaluronidase; Insulin; Insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrails.gov.
    • 28 Jun 2010 Acutal patient number (n=23) as reported by ClinicalTrials.gov.
    • 07 May 2010 Results will be presented at the President's Poster Session at the American Diabetes Association (ADA) 70th Scientific Sessions, as reported by Halozyme Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top